Loss of the KN Motif and AnKyrin Repeat Domain 1 (KANK1) Leads to Lymphoid Compartment Dysregulation in Murine Model

Genes (Basel). 2023 Oct 16;14(10):1947. doi: 10.3390/genes14101947.

Abstract

The KN Motif and AnKyrin Repeat Domain 1 (KANK1) is proposed as a tumour suppressor gene, as its expression is reduced or absent in several types of tumour tissue, and over-expressing the protein inhibited the proliferation of tumour cells in solid cancer models. We report a novel germline loss of heterozygosity mutation encompassing the KANK1 gene in a young patient diagnosed with myelodysplastic neoplasm (MDS) with no additional disease-related genomic aberrations. To study the potential role of KANK1 in haematopoiesis, we generated a new transgenic mouse model with a confirmed loss of KANK1 expression. KANK1 knockout mice did not develop any haematological abnormalities; however, the loss of its expression led to alteration in the colony forming and proliferative potential of bone marrow (BM) cells and a decrease in hematopoietic stem and progenitor cells (HSPCs) population frequency. A comprehensive marker expression analysis of lineage cell populations indicated a role for Kank1 in lymphoid cell development, and total protein analysis suggests the involvement of Kank1 in BM cells' cytoskeleton formation and mobility.

Keywords: KANK1; germline (GL); lymphoid dysregulation; murine model; myelodysplastic neoplasms (MDS).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing* / metabolism
  • Animals
  • Ankyrin Repeat / genetics
  • Cytoskeletal Proteins / metabolism
  • Disease Models, Animal
  • Humans
  • Mice
  • Neoplasms*

Substances

  • Adaptor Proteins, Signal Transducing
  • Cytoskeletal Proteins
  • KANK1 protein, human
  • Kank1 protein, mouse

Grants and funding

This project was supported by a center grant from the Novo Nordisk Foundation (Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant NNF17CC0027852), the Greater Copenhagen Health Science Partners (Clinical Academic Group in Translational Hematology), and Danish Cancer Society (R302-A17259). This project is part of the Danish Research Center for Precision Medicine in Blood Cancers funded by Danish Cancer Society grant R223-A13071.